Company news
Celularity Inc. (NASDAQ:CELU) news
Every Celularity Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform
August 27, 2026
Celularity Provides Update Regarding Nasdaq Listing Compliance
August 25, 2026
Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies
June 4, 2026
Celularity Appoints Rick Gonzalez as Chief Commercial Officer
June 3, 2026
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation
May 1, 2026
Celularity : Annual Report for Fiscal Year Ending December 31, 2025 (Form 10-K)
April 30, 2026
Celularity Announces Closing of Transaction with NexGel
April 21, 2026
Celularity Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
April 17, 2026
NEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity Transaction
April 15, 2026
NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction
April 8, 2026
NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity
March 31, 2026
Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities
March 12, 2026
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy
March 10, 2026
Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses
February 10, 2026
Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations
December 26, 2025
Celularity Announces Closing of Financing Transactions
December 22, 2025
Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision
December 18, 2025
Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care
October 30, 2025
Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease
October 14, 2025
Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance
September 3, 2025
Celularity Receives Nasdaq Notice Regarding Form 10-Q
August 22, 2025
Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt
August 18, 2025
Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law
July 9, 2025
Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies
July 1, 2025
Celularity Announces Chief Financial Officer Transition
June 10, 2025
Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology
June 2, 2025
Celularity Announces Full Year 2024 Operating and Financial Results
May 9, 2025
Celularity Receives Nasdaq Notice Regarding Non-Payment of Nasdaq Fees
April 25, 2025
Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products
April 14, 2025
Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology
April 7, 2025
Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products
February 25, 2025
Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company
February 24, 2025
Celularity Inc. Announces Resolution of Nasdaq Listing Compliance Matter
December 10, 2024
Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023
December 6, 2024
Celularity Inc. Announces Receipt of Nasdaq Notification
November 27, 2024
Celularity’s Strategic Partner Announces Groundbreaking for State-of-the-Art Stem Cell & Regenerative Medicine Center in Asia Pacific
November 20, 2024
Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million
November 7, 2024
Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel
October 23, 2024
Celularity Provides Corporate Update
October 22, 2024
Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal
October 18, 2024
Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.
October 16, 2024
Celularity to Present at H.C. Wainwright’s 26th Annual Global Investment Conference
September 5, 2024
Celularity Appoints Richard J. Berman to its Board of Directors
August 28, 2024
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
August 23, 2024
Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023
July 31, 2024
SANUWAVE Provides Corporate Update
June 4, 2024
Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting
June 3, 2024
Celularity Data Published in Journal for ImmunoTherapy of Cancer Reveals Benefits of Placental Circulating T Cells for CAR-T Therapy
May 14, 2024
Celularity Inc. to Host Investor and Analyst Research & Development Day
April 22, 2024
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing
April 19, 2024